Infectious Disease Therapeutics Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the infectious disease therapeutics market?
The sector of infectious disease therapeutics has witnessed robust growth in recent times. The market, which was valued at $141.08 billion in 2024, is projected to escalate to $151.04 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this historic growth include an escalated rate of infectious and viral diseases, an increased understanding and demand for diagnostic procedures, a surge in desire for fast, accurate diagnostic tests, a growing need for affordable generic medications, an increased rate of infectious illnesses, as well as the mounting importance of antimicrobial stewardship.
What will be the infectious disease therapeutics market size in the future?
The market size for therapeutics targeting infectious diseases is anticipated to witness sturdy expansion in the forthcoming years, rising to $196.5 billion by 2029 at a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period can be credited to escalating investments, the broadening scope of clinical trial studies, a rising count of clinical trials, heightened emphasis on prevention of infectious diseases, increased cognisance about early detection, and amplified awareness and funding. Key trends expected during the forecast period involve collaborations, product endorsements, investments, along with research and advancements in therapeutics.
Get your infectious disease therapeutics market report here!
What main drivers are fueling expansion in the infectious disease therapeutics market?
The increasing occurrence of infectious illnesses is projected to stimulate the expansion of the infectious disease therapeutics market. Pathogenic microorganisms such as bacteria, viruses, fungi, parasites, or prions are known to cause these diseases. Various major elements contribute to the escalation of these diseases which includes changes in climate and environmental conditions, increased resistance to antimicrobial agents, weakened immunity systems, frequent animal interaction, and ecological disruptions. The role of infectious disease therapeutics in treating infections, lessening disease and mortality rates, and controlling the transmission of these diseases within communities and in larger populations is critical. To illustrate, in November 2023, the Centers for Disease Control and Prevention, a governmental institution based in the US, reported that 8,331 cases of tuberculosis (TB) with an incidence rate of 2.5 per 100,000 individuals were registered in the country in 2022. This signifies a 5.9% upsurge in the number of cases and a 5.5% climb in the incidence rate compared to 2021. Hence, this upward trend in infectious illnesses is a significant factor propelling the growth of the infectious disease therapeutics market.
What key areas define the segmentation of the global infectious disease therapeutics market?
The infectious disease therapeutics market covered in this report is segmented –
1) By Type: Drugs, Vaccines
2) By Disease: Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases
3) By End-User: Hospitals And Clinics, Retail Pharmacies, Research Organizations, Other End Users
Subsegments:
1) By Drugs – Antibiotics, Antivirals, Antifungals, Antiparasitics, Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)
2) By Vaccines – Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Mrna Vaccines, Dna Vaccines, Toxoid Vaccines
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp
Who are the dominant players expanding their reach in the infectious disease therapeutics market?
Major companies operating in the infectious disease therapeutics market are Pfizer Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Thermo Fisher Scientific, AstraZeneca, Abbott Laboratories, Novartis International AG, Danaher Corporation, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceutical, Siemens Healthineers, Moderna Inc., Becton, Dickinson, and Company, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories, Qiagen N.V., Ortho Clinical Diagnostics, BioCryst Pharmaceuticals Inc.
What are the key trends shaping the future of the infectious disease therapeutics market?
Main participants in the infectious disease therapeutics landscape are channeling investments towards infectious disease medications, with the aim of devising more potent remedies, fighting antimicrobial resistance, diversifying their product offerings, and tackling newly arising infectious threats. The ultimate goals of these investments are bettering patient results, satisfying unfulfilled medical needs, and aiding global public health endeavors to regulate and manage infectious diseases. For example, in June 2022, GSK, a healthcare firm from the UK, deployed £1 billion ($1.09 billion) to preemptively tackle infectious diseases prevalent in lower-income countries. This endeavor is targeted towards driving research and development activities to fight diseases that unduly impact these areas. The imbalance in health research financing and resources between wealthier and less affluent countries stresses the immediate need for such pre-emptive investments to equitably enhance public health.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15594
Which regions are emerging as leaders in the infectious disease therapeutics market?
North America was the largest region in the infectious disease therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
High Level Disinfection Services Global Market Report 2024
Veterinary Anti-infectives Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/veterinary-anti-infectives-global-market-report
Infection Control Supplies Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/infection-control-supplies-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
